Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
Nancy W. Y. Leung, Ching‐Lung Lai, Ting‐Tsung Chang, Richard Guan, Chuan‐Mo Lee, Keng‐Yeen Ng, Seng‐Gee Lim, Pui‐Chee Wu, Julie C. Dent, Sally Edmundson, Lynn D. Condreay, Rong‐Nan Chien, on behalf of the ASIA HEPATITIS LAMIVUDINE STUDY GROUP – 30 December 2003 – A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo.